Prolonged NLRP3 activation occurs in different chronic inflammatory, metabolic and degenerative diseases such as gout, type 2 diabetes or Alzheimer (Daniels et al., 2016; Heneka et al., 2013; Masters et al., 2010; Martinon et al., 2006), therefore selective small molecules that block NLRP3 are emerging as novel anti-inflammatory therapies (Cocco et al., 2017; Coll et al., 2015; Tapia-Abellán et al., 2019). Here, NLRP3 is linked to type 2 diabetes mellitus.